English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met. Data as of 30/09/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ❌ Debt failed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2023 → 2024: 37.36%
Price change 2024 → 2025: 55.61%
Price change 2025 → 2026: 13.69%
Price change 2026 (year to date): 14.92%
Financial growth
Revenue CAGR (6 years): 5.47%
Earnings CAGR (6 years): 18.54%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.61
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 57.48
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 10.24% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="SDZ.SW" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Sandoz Group AG | 69.2 | 0.61 | +5.5 % | 🔒 |
| Illumina, Inc. | 46.9 | 0.94 | +11.0 % | – |
| ResMed Inc. | 21.4 | 0.14 | +10.8 % | ★ 4/5 |
| Merck KGaA | 18.0 | 0.42 | +5.6 % | – |
| Sartorius Stedim Biotech S.A. | 50.4 | 0.64 | +13.7 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Sandoz Group AG over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 8.6 bn | 409 m | 4.8 % | n/a |
| 2021 | 8.8 bn | 828 m | 9.4 % | +3.3 % |
| 2022 | 8.6 bn | 784 m | 9.1 % | -2.5 % |
| 2023 | 10.0 bn | 77.0 m | 0.8 % | +16.0 % |
| 2024 | 9.1 bn | 1.0 m | 0.0 % | -8.6 % |
| 2025 | 11.2 bn | 957 m | 8.6 % | +22.3 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Sandoz Group AG over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 36.4 m | 74.0 m | 933 m | 1.2 bn | 1.7 bn |
| Total Debt | 284 m | 309 m | 4.6 bn | 4.9 bn | 5.7 bn |
| Net Debt | 248 m | 309 m | 3.4 bn | 3.7 bn | 3.9 bn |
| Equity | 7.4 bn | 77,139 | 7.3 bn | 8.2 bn | 9.4 bn |
| Total assets | 16.0 bn | 17.6 bn | 19.4 bn | 19.9 bn | 22.0 bn |
| Operating cash flow | 1.2 bn | 1.2 bn | 362 m | 656 m | 1.6 bn |
| Investments (capex) | 382 m | 408 m | 568 m | 404 m | 493 m |
| Free cash-flow | 856 m | 760 m | -243 m | 60.0 m | 810 m |
| Share buybacks | 0 | 0 | 0 | 12.0 m | 0 |
| Dividends paid | 0 | 0 | 0 | 215 m | 315 m |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Sandoz Group AG compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Sandoz Group AG | 43.3 bn | 69.2 | 8.6 % |
| Viatris Inc. VTRS | 21.9 bn | 7.5 | -24.6 % |
| Merck KGaA MRK.DE | 73.6 bn | 18.0 | 12.4 % |
| Aurobindo Pharma Limited AUROPHARMA.NS | 10.2 bn | 26.3 | 11.0 % |
| Lupin Limited LUPIN.NS | 9.7 bn | 15.8 | 14.4 % |
| Mankind Pharma Limited MANKIND.NS | 10.8 bn | 47.7 | 16.3 % |
| Sun Pharmaceutical Industries Limited SUNPHARMA.NS | 44.9 bn | 34.5 | 20.8 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 06/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Sandoz Group AG publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 12.3 bn | 2.2 bn | 4.15 (3.94 / 5.10) | n/a | 13 |
| 2027 | 13.0 bn | 2.4 bn | 4.67 (4.47 / 5.66) | n/a | 13 |
| 2028 | 13.7 bn | 2.7 bn | 5.24 (4.24 / 6.58) | n/a | 10 |
Amounts in USD, the reporting currency.
Track record against expectations: reported EPS above consensus 2 times over the last 5 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Sandoz Group AG: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (CHF), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 13/04/2026 | 0.800 CHF | 15/04/2026 |
| 17/04/2025 | 0.600 CHF | 23/04/2025 |
| 03/05/2024 | 0.450 CHF | 07/05/2024 |
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 05/08/2026 | 1.38 | 1.41 | -2.1 % |
| 25/02/2026 | 1.44 | 1.41 | +2.1 % |
| 07/08/2025 | 1.46 | 1.46 | 0.0 % |
| 05/03/2025 | 1.59 | 1.63 | -2.5 % |
| 29/10/2024 | 1.01 | 0.90 | +12.3 % |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Sandoz Group AG.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Sandoz Group AG
What is the Sandoz Group AG share price?
Latest recorded price: 83.78 CHF on 06/11/2026, for a market cap of 44.2 bn USD.
What is the revenue of Sandoz Group AG?
11.2 bn USD for fiscal year 2025, with net income of 957 m USD (net margin 8.6 %).
Does Sandoz Group AG pay a dividend?
Yes. Latest dividend: 0.800 CHF per share, ex-dividend on 13/04/2026. Over 12 months: 0.800 CHF.
When does Sandoz Group AG report its next earnings?
The next release is expected on 17/02/2027. EPS expected by analysts: 1.88.
What do analysts say about Sandoz Group AG?
Out of 17 analysts: 7 buy or strong buy, 8 hold, 2 sell or strong sell.
What is the P/E ratio of Sandoz Group AG?
Trailing 12-month P/E of 70.4.
Is Sandoz Group AG stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN CH1243598427).
How many employees does Sandoz Group AG have?
22,049 full-time employees according to the latest published profile.
Who runs Sandoz Group AG?
Richard Saynor is the company's chief executive.